request@lex-conform.com

PRODUCT COMPLIANCE & GLOBAL CONFORMITY

LEXCONFORMProduct regulatory services

Regulatory guidance and project coordination

CE Marking Cost For Medical Devices In The Eu

Scope and evidence must be confirmed before any paid tests or filings.

There is no EU charge for putting the CE symbol on a medical device. The meaningful budget is the manufacturer's cost of demonstrating conformity with Regulation (EU) 2017/745 (MDR), including evidence, quality processes and, when required, a notified body. A price for a ‘CE certificate’ without a device description is not a reliable quote.

This guide concerns medical devices governed by the MDR, not in-vitro diagnostic devices governed by the IVDR. Published notified-body prices below are real tariffs from one provider, not an EU-wide charge or a promise of the total cost.

First decide which assessment route you are paying for

The device’s intended purpose, risk classification and special features determine whether a notified body must be budgeted. Do not treat these rows as a substitute for documented classification under MDR Annex VIII.

Device situation Budget consequence Essential qualification
Ordinary class I device Normally no notified-body assessment line; manufacturer still funds MDR documentation, evaluation, controls and surveillance. Excludes sterile, measuring and reusable surgical-instrument class I subsets; special cases need separate examination.
Class I sterile, measuring or reusable surgical instrument (Is/Im/Ir) Add notified-body charges for the specific limited aspects of the applicable procedure. It is not automatically the full class IIa review; the scope differs for sterility, metrology or reuse.
Class IIa, IIb or III Plan for notified-body application, quality-system audit and applicable technical/clinical review, followed by surveillance. Workload differs with risk, design, clinical evidence, sites and conformity-assessment route.

Before pricing this table, distinguish routine devices from custom-made and investigational devices. A patient-matched or adapted product is not automatically a custom-made device under MDR Article 2(3). Custom-made devices follow Article 52(8) and Annex XIII; investigational devices have distinct rules. In particular, a class III custom-made implantable device must not be budgeted as an ordinary class I self-declaration.

A claim of “self-certification” is not an exemption from MDR requirements. The separate procedural questions belong in the linked process and self-declaration guides.

For an existing device moving from the former MDD/AIMDD framework, budget an eligibility review separately: verify the prior certificate, available evidence and any Article 120 transition conditions before treating its costs as those of a new MDR device.

Build the budget from eight distinct cost buckets

Mark each item as internal staff time, external supplier quote, notified-body tariff or recurring expenditure. Zero is acceptable only when the requirement is demonstrably inapplicable or already covered.

Budget item What to cost / evidence of scope
Regulatory scoping Intended purpose, MDR/IVDR boundary, classification rationale, applicable rules and device-family grouping.
Quality management MDR-compliant quality system, procedures, supplier controls, personnel (including Article 15 PRRC arrangements) and audit readiness; a separately purchased ISO 13485 certificate is not the same line item as MDR conformity assessment.
Technical and clinical evidence Risk management, Annex II/III technical files, clinical evaluation, usability/software/cybersecurity and biocompatibility as applicable; new clinical investigations only if justified by evidence gaps and applicable requirements.
Testing and remediation Test plan, laboratory quotations, samples, shipping, failed-test investigation, design corrections and retests; never assume a test is universally required.
Notified-body work Application, audits, technical/clinical document reviews, certification decision, supplements, travel, subcontractor assessments and follow-up if applicable.
EU authorised representative Written mandate and representative fees where an authorised representative is legally required, notably for manufacturers established outside the EU/EEA; check special territorial arrangements. Importer and distributor duties are separate.
Identification and market entry UDI/data preparation, EUDAMED tasks, translation and labels, packaging; verify any separately applicable national charges rather than inventing an EU registration tariff.
After-market and changes Post-market surveillance, complaints, vigilance, periodic reporting where required, surveillance/renewal audits and design or supplier changes.

Published 2026 tariff: a checkable example, not a market average

MDR Article 50 requires notified bodies to publish standard fees. The Commission’s July 2026 index links to those fee lists. BSI Group The Netherlands (NB 2797) publishes the following MDR fees effective 1 January 2026 (EUR).

BSI NL standard item Published amount How to interpret it
Application €3,024 flat; stated normal range €3,024–€6,048 One administrative component, not the whole certificate.
QMS audit €2,290 per auditor-day Multiply by quoted audit days; travel/time/expenses may be extra.
Technical-document review €4,032 per assessment day (listed 4–12 days) The number of days is device/file dependent; do not use 4 for every product.
Certificate decision €504 flat (normal range €504–€756) Some product-specific decisions have a different tariff.
Annual certificate maintenance €2,520 flat (normal range €2,520–€10,584) A recurring charge, not a one-time application fee.

The same BSI list prices unannounced audits at €4,810 per day (normal range €4,810–€8,842/day), and clinical evaluation assessment reports at €4,032/day where applicable. Rates may exclude travel, laboratories and external consultations. Ask the notified body for an itemised project quote and verify designation scope through NANDO.

Worked calculation and three realistic budget situations

A transparent illustration using only listed BSI unit prices (not an estimate for any particular device):

€3,024 application + (2 × €2,290 audit days) + (4 × €4,032 technical-review days) + €504 certificate decision = €24,236.

The two audit days are a hypothetical assumption; actual days are unknown until scoped. This subtotal deliberately excludes clinical review, testing, QMS build, authorised representation, travel, tax, further review, surveillance and subsequent years. It must never be quoted as a fixed CE-marking price.

Scenario First major cost decision What remains unknown
Simple non-sterile class I device Validate self-declaration route; cost documentation, evaluation, QMS and PMS before buying a notified-body package. Proof needed, internal capability, tests and EU representation.
Class I device supplied sterile Budget limited notified-body sterility assessment plus validation/testing and the normal manufacturer obligations. Sterilisation method, subcontractors, sites and sample/test needs.
Class IIb device, including software only if classified IIb Reserve separate lines for notified-body audit/review, software/electrical or other relevant testing, clinical evidence and future surveillance. Device rules, clinical gaps, variants, audit days and specialist review.

The example cannot establish a total price for Class Is/Im/Ir: limited notified-body assessment of sterile, measuring or reuse-related aspects requires a separately scoped quote.

Five avoidable reasons budgets expand

Reserve a contingency without presenting an invented percentage. The main controllable cost multipliers are:

  • Classifying before freezing intended purpose and claims: a revised claim can change the assessment route.
  • Bundling unrelated models as one family without documented justification: reviewers may require more separate files or sampling.
  • Requesting a test package before a gap assessment: unsuitable samples or test standards can require repeat work.
  • Submitting inconsistent clinical, risk, design and labelling evidence: deficiency rounds consume assessment time.
  • Ignoring supplier sites, sterile operations, travel, annual audits and product changes in a one-time quote.

Send this quote pack before requesting a fixed commercial proposal

A quote is preliminary when these inputs are missing. Use “unknown” rather than guess:

  • Legal manufacturer and country of establishment; whether an EU authorised representative is already appointed.
  • Plain-language intended medical purpose, claims, indications, users and patient population.
  • Proposed class and MDR Annex VIII rule with reasoning; sterile, measuring, reusable, implantable and software features.
  • Product families, variants, Basic UDI-DI strategy and expected number of technical-documentation submissions.
  • Manufacturing and critical subcontractor sites, locations, employee count and current QMS maturity.
  • Existing clinical evaluation, investigations, published literature and unresolved evidence gaps.
  • Testing matrix, available reports, applicable standards and samples; any previous failures.
  • Target market languages, labels/instructions, EUDAMED/UDI readiness and expected launch window.
  • Requested quote format: per item, assessment days, assumptions, travel, external services, re-review, annual charges, taxes and cancellation terms.

A five-step procurement and budget-control sequence

Use separate approval gates; the sequence avoids paying for the wrong service:

  1. Document device qualification and classification; resolve MDR versus IVDR and any special regime.
  2. Map evidence gaps and identify reusable, current test and clinical reports; scope what must actually be purchased.
  3. If required, shortlist MDR-designated notified bodies with relevant NANDO scope; compare their published tariff bases.
  4. Obtain line-item proposals from test labs, notified body, representative and advisers; assign deliverables and exclusions.
  5. Approve a launch budget and a recurring-year budget separately; track changes, deficiency rounds and retest authorisation.

Do not stop the budget at the first CE mark

For devices requiring notified-body involvement, plan ongoing certificate-related charges and audits as agreed and required; a one-year price is not the full commercial commitment. MDR Articles 83–86 also establish post-market surveillance/reporting duties, with obligations differing by class.

Since 28 May 2026, four EUDAMED modules have been mandatory: Actor, UDI/Device, Notified Bodies & Certificates, and Market Surveillance. Their obligations differ by role: manufacturers must assess applicable actor and device registrations, notified bodies enter certificate information, and the Market Surveillance module is managed by competent authorities. Check transitional arrangements for existing devices; these modules do not create a universal EU registration fee.

Use a simple horizon model: initial evidence + initial review + launch operations + sum of annual surveillance/representation/PMS costs + planned change/retest reserve. A quote cannot be reliable until the device class, evidence condition and review scope are established.

Cost questions that change a purchase decision

Does a CE mark itself cost money?

No fee is charged for affixing the CE symbol. You must still pay any applicable assessment, documentation, testing and ongoing compliance costs.

Can a class I device avoid notified-body fees?

Often, if it is an ordinary class I MDR device outside sterile, measuring and reusable-surgical-instrument subsets; the manufacturer still has substantial compliance duties. Verify classification first.

Can I multiply BSI’s published rate by one day and call it my quote?

No. BSI lists 4–12 days for technical-documentation assessment and separate audit, application, certificate, travel and follow-up charges. The number of days must be scoped.

Will an ISO 13485 certificate replace the MDR notified-body assessment?

No. A QMS certification purchase and the MDR conformity-assessment route are different questions. Confirm which QMS evidence and audits the chosen MDR route actually requires.

Do medical-device CE costs include clinical trials and EUDAMED registration?

Not automatically. New clinical investigations depend on the device and available evidence; EUDAMED compliance requires work, but do not assume one universal EU registration tariff. Ask for both lines to be explicitly included or excluded.

Official regulatory and published tariff sources

Responsible for publication: Khachatrian Razmik

Last updated: 2026-10-16

Related guidance

© LEX CONFORM / Lex Agency LLC.All rights reserved.